Unicycive Therapeutics Beats Loss Estimates

Unicycive Therapeutics, Inc. saw its shares rise 2.00% in premarket trading on Wednesday, August 12, 2026, following a second-quarter earnings report. The clinical-stage biotechnology company announced a loss of $0.06 per share, significantly outperforming Wall Street's consensus forecast of a $0.48 per share loss.

The company's net loss for the second quarter ended June 30, 2026, was $1.7 million. This represents a substantial improvement from the $6.5 million net loss recorded in the same period of the prior year. This reduction was largely attributed to an $8.0 million gain from a change in the fair value of warrant liability.

Despite improved financial metrics, Unicycive continues to invest in its development pipeline. Operating expenses increased, with research and development costs rising to $2.8 million from $1.8 million year-over-year, primarily due to higher stock-based compensation. General and administrative costs also climbed to $7.4 million from $5.2 million, reflecting increased stock-based compensation and commercial launch preparations.

Unicycive is actively pursuing regulatory approval for oxylanthanum carbonate (OLC), a treatment for hyperphosphatemia in dialysis patients. In June 2026, the company received a Complete Response Letter from the U.S. Food and Drug Administration. The letter cited deficiencies related to a third-party manufacturing facility, not clinical efficacy or safety. A facility inspection by the FDA is now pending for the third-party vendor. Unicycive expects to resubmit its New Drug Application once this inspection is successfully completed, expressing confidence in OLC's potential to improve patient care.

The company anticipates its current cash runway will extend into 2027, providing runway for ongoing clinical and commercial development activities.